or Try an Advanced Search...

    Technical Analysis for OKYO - OKYO Pharma Limited

    Grade Last Price % Change Price Change
    D 1.49 -1.32% -0.02
    OKYO closed down 1.32 percent on Wednesday, May 15, 2024, on 13 percent of normal volume. It was able to find support at its 50 day moving average.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Flat
    Historical OKYO trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    50 DMA Support Bullish 0.00%
    Inside Day Range Contraction 0.00%
    Gapped Down Weakness 0.00%
    20 DMA Support Bullish -1.32%
    50 DMA Support Bullish -1.32%
    Pocket Pivot Bullish Swing Setup -1.32%
    Earnings Movers Other -1.32%
    20 DMA Support Bullish 0.68%
    50 DMA Support Bullish 0.68%
    Older End-of-Day Signals for OKYO ...

       Recent Intraday Alerts

    Alert Time
    Gap Down Partially Closed about 11 hours ago
    Possible NR7 about 11 hours ago
    Possible Inside Day about 11 hours ago
    Gapped Down (Partial) about 14 hours ago
    Down 5% about 14 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    OKYO Chart by TradingView
    Basic chart:

    Profile

    OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) is a biotechnology company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. OKYO’s research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which OKYO believes plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need. OKYO’s therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. The Company is presently developing OK-101, its lead preclinical product candidate, for the treatment of dry-eye disease “DED”. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Clinical Medicine Immunology Pain Eye Diseases Inflammatory Uveitis Allergic Conjunctivitis Dry Eye Disease Conjunctivitis Measles Treatment Of Dry Eye Disease

    Is OKYO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 8 OKYO Pharma Announces Participation in May 2024 Investor Conferences
    Apr 30 OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
    Apr 8 OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
    Apr 2 OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
    Mar 22 OKYO Pharma gains after positive results from Phase 2 dry eye disease trial
    Mar 22 OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
    Mar 21 OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
    Mar 20 OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
    Feb 9 OKYO Pharma gains on receiving FDA nod of IND for OK-101 in neuropathic corneal pain
    Feb 9 OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
    See more OKYO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.07
    52 Week Low 0.9201
    Average Volume 83,793
    200-Day Moving Average 1.66
    50-Day Moving Average 1.46
    20-Day Moving Average 1.47
    10-Day Moving Average 1.49
    Average True Range 0.10
    RSI (14) 52.15
    ADX 14.15
    +DI 15.96
    -DI 13.55
    Chandelier Exit (Long, 3 ATRs) 1.28
    Chandelier Exit (Short, 3 ATRs) 1.59
    Upper Bollinger Bands 1.56
    Lower Bollinger Band 1.37
    Percent B (%b) 0.63
    BandWidth 12.48
    MACD Line 0.01
    MACD Signal Line 0.01
    MACD Histogram 0.0026
    Fundamentals Value
    Market Cap 49.52 Million
    Num Shares 33.2 Million
    EPS -0.61
    Price-to-Earnings (P/E) Ratio -2.44
    Price-to-Sales 0.00
    Price-to-Book 14.11
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.63
    Resistance 3 (R3) 1.61 1.56 1.60
    Resistance 2 (R2) 1.56 1.52 1.56 1.59
    Resistance 1 (R1) 1.52 1.50 1.54 1.54 1.59
    Pivot Point 1.47 1.47 1.48 1.47 1.47
    Support 1 (S1) 1.43 1.43 1.45 1.45 1.39
    Support 2 (S2) 1.38 1.41 1.38 1.39
    Support 3 (S3) 1.34 1.38 1.38
    Support 4 (S4) 1.36